U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

  

FORM 10-Q

  

x	Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2012

 

¨	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from                     to                     .

Commission File Number 001-34661

 

Dehaier Medical Systems Limited

 

(Exact name of registrant as specified in its charter)

 

  

British Virgin Islands		Not Applicable
(State or other jurisdiction of		(I.R.S. employer
incorporation or organization)		identification number)

 

Room 501, 83 Fuxing Road

Haidian District, Beijing 100856

People’s Republic of China

(Address of principal executive offices and zip code)

 

+86 (10) 5166-0080

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

 

Large accelerated filer		¨		Accelerated filer		¨
Non-accelerated filer		¨ (Do not check if a smaller reporting company)		Smaller reporting company		x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. The Company is authorized to issue 18,307,038 Shares. As of August 13, 2012, the Company has issued and outstanding 4,570,000 Shares.

 

 

DEHAIER MEDICAL SYSTEMS LIMITED

FORM 10-Q

INDEX

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS		ii
PART I.	FINANCIAL INFORMATION	1
Item 1.	Financial Statements	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	12
Item 4.	Controls and Procedures	12
PART II.	OTHER INFORMATION	13
Item 1.	Legal Proceedings	13
Item 1A.	Risk Factors	13
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	13
Item 3.	Defaults upon Senior Securities	13
Item 4.	Mine Safety Disclosures	13
Item 5.	Other Information	13
Item 6.	Exhibits	13
FINANCIAL STATEMENTS		F-1

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

We have made statements in this quarterly report that constitute forward-looking statements. Forward-looking statements involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “we believe,” “we intend,” “may,” “should,” “could” and similar expressions. These statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances or achievements expressed or implied by the forward-looking statements.

 

Examples of forward-looking statements include:

 

•

projections of revenue, earnings, capital structure and other financial items;

 

•

statements of our plans and objectives;

 

•

statements regarding the capabilities and capacities of our business operations;

 

•

statements of expected future economic performance; and

 

•

assumptions underlying statements regarding us or our business.

 

The ultimate correctness of these forward-looking statements depends upon a number of known and unknown risks and events. Many factors could cause our actual results to differ materially from those expressed or implied in our forward-looking statements. Consequently, you should not place undue reliance on these forward-looking statements.

 

The forward-looking statements speak only as of the date on which they are made, and, except as required by law; we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.

 

In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

 

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update this forward-looking information. Nonetheless, the Company reserves the right to make such updates from time to time by press release, periodic report or other method of public disclosure without the need for specific reference to this Report. No such update shall be deemed to indicate that other statements not addressed by such update remain correct or create an obligation to provide any other updates.

 

 

PART I.         FINANCIAL INFORMATION

 

Item 1.

Financial Statements

 

See the financial statements following the signature page of this report, which are incorporated herein by reference.

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of the company’s financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this report. In this report, the terms “we,” “the Company” and “our” refer to Dehaier Medical Systems Limited, a British Virgin Islands company (“Dehaier”), Beijing Dehaier Technology Company Limited, our variable interest entity in the People’s Republic of China (“BTL”) and Beijing Dehaier Medical Technology Company Limited, our operating subsidiary in the People’s Republic of China (“BDL”). This discussion contains forward-looking statements that involve risks and uncertainties. Actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various factors.

 

This section should be read together with the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, which was filed on March 19, 2012.

 

Overview

 

We are a company in the business of developing and distributing medical devices. We have been focusing on the respiratory and oxygen homecare industry in particular since 2006.

 

We design, develop and market our own branded products and medical components. Since we do not operate any fully scaled manufacturing facilities, we contract some of the medical components to outside manufacturers in China. Most of our branded products require light assembly by us before distribution.

 

We also distribute products designed and manufactured by other companies. We broaden our product portfolio through distribution agreements with international manufacturers, and most of the products we distribute are imported. Our distribution offerings are mostly medical equipment used in the operating room, the intensive care unit (“ICU”) and the emergency room.

 

While we sell our products primarily through distributors, we also make direct sales to hospitals, clinics and government health bureaus. We continue to further our market reach by introducing newer and more advanced product lines that address different end-user needs.

 

Business Development

 

In April 2012, we renewed our strategic cooperation agreement with Timesco of London Ltd. The agreement appoints us as the exclusive distributor for Timesco’s CXL and Eclipse series laryngoscope products in mainland China for three years.

 

In May 2012, we extended our exclusive distribution authorization with INTERMEDICAL (“IMD”), to distribute its RADIUS C-arm X-ray machines in mainland China. The extended term runs through 2014.

 

In June 2012, we entered a three-year strategic mutual cooperation agreement with HEYER Medical AG (“Heyer”). According to this agreement, we will continue to be one of the key Chinese distributors for Heyer’s anesthesia machines and the exclusive distributor of its nebulizers in China.

 

 

Also in June 2012, we co-developed a “High-Efficiency Oxygen Inhaler” with Dr. Ding Jianzhang of Beijing Haidian Hospital. This inhaler is expected to begin selling in mainland China in the third quarter of 2012. The portable device is designed for use in homecare oxygen therapy, emergency treatment, disaster relief activities and high-altitude settings.

 

In July 2012, we received approval from China’s State Food and Drug Administration (“SFDA”) for our proprietary homecare medical CPAP device, the DHR-CPAP-C5. The certificate is valid until July 1,2016 (subject to renewal) and allows us to sell the product in mainland China.

 

Also between April and June 2012 we obtained software copyrights from China’s National Copyright Administration for four of our proprietary technologies, including (1) Analysis and Monitoring Software of Adsorption Tower Oxygen Generation Process, (2) Dehaier Homecare CPAP Controlling Software, (3) Ventilator of CPAP Controlling Software and (4) Air Compressor Controlling Software. These copyrights have been approved for 50 years from the grant date.

 

Growth Strategies

 

We plan to build our brand name domestically as both a distributor and a trusted partner by leveraging our relationships with healthcare professionals, agents and other downstream distributors, maintaining and expanding our customer base, and promoting steady business growth.

 

We plan to broaden the portfolio of products we distribute for other companies by cooperating with more internationally recognized medical equipment manufacturers. We also intend to take advantage of our well-established distribution network to grow sales revenues. By actively participating in state-level contracted healthcare programs, we will continue to expand our key account business and build a higher level of contact and relationships with the government and other healthcare industrial insiders.

 

We plan to expand our product portfolio through continued investment in research and development and pursuing attractive opportunities to acquire complementary products and technologies. We have had steady growth in our brand name homecare medical products. We will expand our distribution channels through many new options, such as third party e-commerce platforms and retail drugstore chains. We plan to leverage our oxygen delivery service platform to introduce our homecare products to customers, generating potential cross-selling opportunities.

 

We have started and intend to continue developing our home oxygen service business in Beijing and eventually expand this service platform to all major markets in China. We also plan to offer more value-added services to our customers based on this platform. Our long-term goal is to provide our customers an all-in-one solution in the home healthcare field. Furthermore, we will continue to leverage our existing network of consumer experience centers, or CECs, to showcase our new products and services, such as our home oxygen services.

 

We will continue to expand into overseas markets and establish a distribution network, through distribution agreements, OEM partnerships, direct sales force efforts and e-commerce platforms. We will build our brand name by actively participating in international trade shows and other marketing activities. To the extent we have adequate demand for our homecare medical products abroad, we will continue seeking regulatory approval to sell these products in the United States and Europe.

 

Results of Operations

 

Overview

 

For the six and three months ended June 30, 2012 and 2011, our total revenues amounted to approximately $10.30 million, $10.67 million, $6.98 million and $7.71 million, respectively. Our revenues are subject to value added tax (“VAT”), sales returns and trade discounts. We deduct these amounts from our gross revenues to arrive at our total revenues. Our net income attributable to Dehaier for the six and three months ended June 30, 2012 and 2011 was approximately $1.82 million, $1.94 million, $1.69 million and $1.74 million, respectively. Both the revenue and net income attributable to Dehaier decreased slightly, mainly due to the Company’s operating strategy adjustments. While we continuously developed our sales channels on traditional medical devices sales, in recent months, we also began adjusting our strategy to expand into government procurement projects and the burgeoning respiratory and oxygen homecare market.

 

 

Factors Affecting Our Results of Operations – Generally

 

We believe the most significant factors that directly or indirectly affect our sales revenues and net income are: 

 

•

the level of acceptance of our products among hospitals and other healthcare facilities;

 

•

our ability to price our products at levels that provide favorable margins;

 

•

new products introduced by us and our competitors;

 

•

our ability to attract and retain distributors and key customers;

 

•

our continued investment in research and development activities and our retention of key employees;

 

•

changes in China’s macro-economic environment and healthcare-related government policies and legislation; and

 

•

global economic conditions.

 

Revenues

 

Our total revenues are derived from our medical devices and our respiratory and oxygen homecare products and services.

 

Medical Devices (Including Related Supporting Products) – Our Proprietary and Distributed Products

 

We derive revenues in our medical devices product line from the sale of C-arm X-ray systems, anesthesia machines, medical ventilators, general hospital products and related supporting products. Our medical device line is our largest product line and has the most extensive market penetration. We anticipate that we will continue to experience revenue growth in our medical devices line as we further develop our market through the introduction of new advanced product offerings and the participation in favorable government programs. In addition, we have recently begun to engage in state-level healthcare projects. We may procure high-end medical equipment for our clients, which may not necessarily be part of our existing distributed brands portfolio. We refer to these kinds of contracted projects as “key account business.” Although this business may carry lower margins, the contract value for such business is typically larger and can contribute materially to our revenues.

 

Respiratory and Oxygen Homecare Products and Home Oxygen Therapy Service (or “HOTS”)

 

We derive revenues in our respiratory and oxygen homecare line from sales of oxygen concentrators, CPAP devices, and portable sleep diagnostics devices. We anticipate that, on a percentage basis, revenues from our respiratory and oxygen homecare product line will increase more rapidly than total revenues in the near term, as we introduce new and more advanced products. We expect to develop our market for respiratory and oxygen homecare market in China and internationally through the use of distributors as well as through our direct sales platform.

 

In addition, we launched our home oxygen therapy service (“HOTS”) in Beijing in the third quarter of 2011. In 2012, management will focus on laying a solid foundation, such as the delivery network, rather than generating considerable revenue.

 

Our ability to increase our revenues depends in large part on our ability to (i) increase the market penetration of our existing products, (ii) successfully identify, develop, introduce and commercialize, in a timely and cost-effective manner, new and upgraded products and (iii) enter into international markets in the future. Generally, we choose to devote our resources to product development efforts that we believe are commercially feasible, can generate significant revenues and margins, and can be introduced into the market quickly.

 

 

Operating Costs and Expenses

 

Our operating costs and expenses consist of cost of revenues, general and administrative expenses, selling expenses and other expenses.

 

Cost of Revenues

 

Cost of revenues primarily includes raw materials, parts for assembly, wages, handling charges, amortization of software copyrights, and other expenses associated with the assembly and distribution of product.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of salaries and benefits and related costs for our administrative personnel and management, fees and expenses of our outside advisers, including legal, audit and valuation expenses, expenses associated with our administrative offices and the depreciation of equipment used for administrative purposes. We expect that our general and administrative expenses will increase, both on an absolute basis and as a percentage of revenue, as we hire additional personnel and incur costs related to the anticipated growth of our business. In addition, we expect to continue to incur significant general and administrative expenses as a public company.

 

Selling Expenses

 

Selling expenses consist primarily of compensation and benefits for our sales and marketing staff, expenses for promotional, advertising, travel and entertainment activities, lease payments for our sales offices, and depreciation expenses related to equipment used for sales and marketing activities. Going forward, we expect our selling expenses to increase, both on an absolute basis and as a percentage of revenue, as we increase our efforts to promote our products, especially our new respiratory and oxygen homecare products.

 

Six Months Ended June 30, 2012 Compared to Six Months Ended June 30, 2011.

 

We believe that historical period-to-period comparisons of operating results should not be relied upon as indicative of future performance.

 

Revenues

 

Our total revenues decreased by 3.44% from $10.67 million for the six months ended June 30, 2011 to $10.30 million for the six months ended June 30, 2012. In the first half-year of 2012, we continuously developed our sales channels for traditional medical devices sales. At the same time, we also began to adjust our operating strategy to expand into government procurement projects and the burgeoning respiratory and oxygen homecare market.

 

Cost of Revenues

 

Our cost of revenues decreased by 7.46% from $6.83 million for the six months ended June 30, 2011 to $6.32 million for the six months ended June 30, 2012. Our efforts to manage our inventory and costs allowed us to decrease our cost of revenues at a faster rate than our revenues declined. The reduction in material consumption caused our gross margins to increase. However, we predict inflation pressures are likely to persist in China, which could lead to an increase in our cost of revenues in the coming quarters.

 

Gross Profit

 

Our gross profit increased from $3.84 million in thesis months ended June 30, 2011 to $3.98 million in the same period of 2012, while our gross margin increased from 35.99% in 2011 to 38.66% in 2012. The management believes such increase in gross margin is the result of operating efficiency.

 

 

Operating Expenses

 

Our operating expenses decreased by 0.95% from $1.71 million for the six months ended June 30, 2011 to $1.69 million for the six months ended June 30, 2012. Our general and administrative and selling expenses generally remained the stable in both 2012 and 2011. We analyzed our six months operating expenses by general and administrative expenses and selling expenses in the following parts.

 

Operating Expenses—General and Administrative Expenses

 

General and administrative expenses consist primarily of salaries and benefits and related costs for our administrative personnel and management, and expenses associated with our research and development, registration of patent and intellectual property rights in China and abroad.

 

Our general and administration expenses increased by 1.51% from $1.02 million for six months ended June 30, 2011 to $1.03 million for the six months ended June 30, 2012, maintained generally the same for the six months ended June 30, 2012 as it was in the same period of 2011.

 

We expect that our general and administration expenses may increase in the near future as a result of further R&D expenditures.

 

Operating Expenses - Selling Expenses

 

Our selling expenses consist primarily of salaries and related expenses for personnel engaged in sales, marketing and customer support functions, and costs associated with advertising and other marketing activities. Our selling expenses decreased by 4.56% from $0.69 million for the six months ended June 30, 2011 to $0.66 million for the six months ended June 30, 2012. These selling expense decreases are a result of operating efficiency. We expect our selling expenses will grow as we invest in strengthening our distribution network, growing relationships with our customers, developing the homecare device market (in particular our oxygen therapy service initiative) and driving top-line growth in these areas.

 

Operating Income

 

As a result of the foregoing, we generated operating income of approximately $2.38 million in the six months ended June 30, 2012, compared to approximately $2.22 million in the same period of 2011. Operating income increased by 7.18%, mainly because of the improvement of gross margin and expense management.

 

Taxation

 

Our income tax expense was approximately $0.42 million in the six months ended June 30,2012, compared to approximately $0.40 million in the same period of 2011, primarily due to an increase in our taxable income.

 

Net Income

 

Our net income was approximately $1.81 million in the six months ended June 30, 2012, compared to approximately $1.95 million in 2011, a decrease by 7.19%, mainly because of a change in the fair value of our warrants liability. We calculate the fair value of our warrants each quarter, resulting in a non-cash liability or benefit, depending on whether the fair value our common shares has increased or decreased over the prior period. Excluding the effects of non-cash change in fair value of our warrants liability (which was a charge to operations of $92,067 and a gain of $149,867 for six months ended June 30, 2012 and 2011, respectively), our net income for the six months ended June 30, 2012 would have been $1,900,990, an increase of 5.65% as compared to $1,799,278 for the same period of 2011. After deduction of non-controlling interest in income, net income attributable to Dehaier was approximately $1.82 million and $1.94 million in the six months ended June 30, 2012 and 2011, respectively.

 

 

Three Months Ended June 30, 2012 Compared to Three Months Ended June 30, 2011.

 

Revenues

 

Our total revenues decreased by 9.46% from $7.71 million for the three months ended June 30, 2011 to $6.98 million for the three months ended June 30, 2012. In the second quarter of 2012, the decrease in revenues was mainly attributed to the company’s operating strategy adjustment. In recent months, the company has made strategic decision by expanding into government procurement projects and homecare oxygen therapy services, while we maintaining our sales growth in our traditional medical devices business. In the short term, this strategy adjustment has caused some temporary softness in our revenue growth. However, the management expects the new strategy to benefit the Company in the future as we rely more on higher margin proprietary products and services.

 

Cost of Revenues

 

Our cost of revenues decreased by 12.90% from $4.87 million for the three months ended June 30, 2011 to $4.24 million for the three months ended June 30, 2012. Our efforts to manage our inventory and costs allowed us to decrease our cost of revenues at a faster rate than our revenues declined. The reduction in material consumption caused our gross margins to increase. However, we predict inflation pressures are likely to persist, which could lead increase our cost of revenues in the coming period.

 

Gross Profit

 

Our gross profit decreased from $2.84 million in the three months ended June 30, 2011 to $2.74 million in the same period of 2012, while the gross margin increased from 36.84% in 2011 to 39.24% in 2012. The management believes such increase in gross margin is a result of operating efficiency improvements.

 

Operating Expenses

 

Our operating expenses decreased by 8.52% from $0.97 million for the three months ended June 30, 2011 to $0.88 million for the three months ended June 30, 2012. Operating expense was divided into general and administrative and selling expenses, which are analyzed below:

 

Operating Expenses—General and Administrative Expenses

 

General and administrative expenses consist primarily of salaries and benefits and related costs for our administrative personnel and management, and expenses associated with our research and development, registration of patent and intellectual property rights in China and abroad.

 

Our general and administration expenses increased by 5.49% from $0.51 million for the three months ended June 30, 2011 to $0.54 million for the three months ended June 30, 2012. This increase was mainly due to the continuous investment in our R&D projects.

 

We expect that our general and administration expenses may increase in the near future as a result of further development in our R&D projects and professional fees for being a public company in the U.S.

 

Operating Expenses - Selling Expenses

 

Our selling expenses consist primarily of salaries and related expenses for personnel engaged in sales, marketing and customer support functions, and costs associated with advertising and other marketing activities. Our selling expenses decreased by 24.32% from $0.45 million for the three months ended June 30, 2011 to $0.34 million for the three months ended June 30, 2012. These selling expense decreases are considered as a result of operating efficiency and effectiveness management. We expect our selling expenses will grow as we invest in strengthening our distribution network, growing relationships with customers, developing the homecare device market (in particular our oxygen therapy service initiative) and driving top-line growth in these areas.

 

 

Operating Income

 

As a result of the foregoing, we generated operating income of approximately $1.93 million in the three months ended June 30, 2012 and 2011.

 

Taxation

 

Tax expenses were calculated by taxable income. Our income tax expense was approximately $0.32 million in the three months ended June 30, 2012, compared to approximately $0.31 million in the same period of 2011.

 

Net Income

 

Our net income was approximately $1.68 million in the three months ended June 30,2012, compared to approximately $1.74 million in 2011, a decrease of 3.51%, mainly because of the increase in financial expenses and change in fair value of warrants.

 

Liquidity and Capital Resources

 

Cash Flows and Working Capital

 

As of June 30, 2012, we had approximately $1.11 million in cash and cash equivalents. As a result of the total cash activities, net cash decreased from $3,694,486 at December 31, 2011 to $1,107,942 at June 30, 2012. This is mainly because we invested in obtaining copyright protection for our software, for our future development. We believe that our currently available working capital of $25,920,190, including cash of $1,107,942, should be adequate to meet our anticipated cash needs and sustain our current operations for at least 12 months. To the extent we engage in acquisitions or other business expansion in the future, we will need to rely on a variety of sources of funding, including but not limited to operating cash and debt/equity financings.

 

Operating Activities

 

Net cash used in operating activities was $767,199 for the six months ended June 30, 2012, as compared to $3,356,331 for the same period in 2011. The reasons for this change are mainly as follows:

 

(i)

For the six months ended June 30, 2011, account receivables increased by $3,451,269, while in the same period of 2012, it increased by $282,688. There is a decrease of $3,168,581 in account receivables. The decrease is attributable to the better aging management, which enhanced the collection of account receivables.

 

(ii)

For the six months ended June 30, 2011, prepayments and other current assets increased by $4,240,759, while in the same period of 2012, it increased by $522,831. There is a decrease of $3,717,928 in prepayments and other current assets. The Company improved its operating efficiency that accelerated the turnover of prepayments and current assets.

 

(iii)

For the six months ended June 30, 2011, other receivables decreased by $2,810, while in the same period of 2012, other receivables increased by $1,670,623. There is a increase of $1,673,433 in other receivables. The increase is mainly because of implement of large contracts that increased the deposit amount.

 

(iv)

For the six months ended June 30, 2011, tax payable increased by $2,022,812, while in the same period of 2012, it decreased by $1,616,959. There is a decrease of $3,639,771 in tax payable. This is mainly because we have settled up the tax payables of previous years since the last quarter of 2011.

 

 

Investing Activities

 

Net cash used in investing activities for the six months ended June 30, 2012 was $2,405,707, compared to $64,660 for the same period of 2011. The cash used in investing activities in each quarter was mainly attributable to capital expenditures for software copyrights.

 

Financing Activities

 

During the first half year 2012, we repaid $1,580,436 of short-term bank loan on maturity and entered into a new loan agreement for $2,373,145. The net amount provided by financing activities was $0.79 million at June 30, 2012.

 

Capital Expenditures

 

We made capital expenditures of approximately $2.4 million and $65 thousand in the six months of 2012 and 2011, respectively. In 2011, our capital expenditures were generally used to purchase machinery for our assembly line, while in 2012, our capital expenditures were mainly used to obtain software copyrights.

 

Off-Balance Sheet Commitments and Arrangements

 

We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder’s equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

 

Tax Matters Applicable to the Company

 

Generally

 

Dehaier is a tax-exempt company incorporated in the British Virgin Islands. BDL and BTL were incorporated in the PRC and are governed by PRC laws.

 

The Company pays PRC enterprise income taxes, value added taxes and business taxes in China for revenues from BDL, and is governed by British Virgin Islands tax laws as to Dehaier.

 

British Virgin Islands Tax

 

We are exempt from all provisions of the Income Tax Act of the British Virgin Islands, including with respect to all dividends, interests, rents, royalties, compensation and other amounts payable by or to persons who are not resident in the British Virgin Islands. Capital gains realized with respect to any of our shares, debt obligations or other securities by persons who are not resident in the British Virgin Islands are also exempt from all provisions of the Income Tax Act of the British Virgin Islands. No estate, inheritance tax succession or gift tax rate, duty, levy or other charge is payable by persons who are not resident in the British Virgin Islands with respect to any of our shares, debt obligations, or other securities. No stamp duty is payable in the British Virgin Islands in relation to a transfer of shares in a British Virgin Islands Business Company.

 

PRC Enterprise Income Taxes

 

PRC enterprise income tax is calculated based on taxable income determined under PRC accounting principles. According to the Foreign-invested Enterprises and Foreign Enterprises Income Tax Law (the “FIE Income Tax Law”) and the related implementing rules, both of which issued in 1991, foreign-invested enterprises established in China are generally subject to an income tax rate of 33% (consisting of 30% enterprise income tax and 3% local income tax). The FIE Income Tax Law and the related implementing rules provide certain favorable tax treatments to qualified foreign invested enterprises.

 

 

The FIE Income Tax Law was replaced by the Enterprise Income Tax Law (the “EIT Law”) as of January 1, 2008. Under the EIT Law, a unified enterprise income tax rate of 25% and unified tax deduction standards will be applied equally to both domestic-invested enterprises and foreign-invested enterprises. Enterprises established prior to March 16, 2007 eligible for preferential tax treatment in accordance with the currently prevailing tax laws and administrative regulations shall, under the regulations of the State Council, gradually become subject to the EIT Law rate over a five-year transition period starting from the date of effectiveness of the EIT Law. The details of the transitional arrangement for the five-year period from January 1, 2008 to December 31, 2012 applicable to enterprises approved for establishment prior to March 16, 2007, such as us, were adopted in January 2008.

 

Furthermore, under the EIT Law, an enterprise established outside of the PRC with “de facto management bodies” within the PRC is considered a resident enterprise and will normally be subject to the enterprise income tax at the rate of 25% on its global income. If the PRC tax authorities subsequently determine that we or any of our non-PRC subsidiaries should be classified as a PRC resident enterprise, then such entity’s global income will be subject to PRC income tax at a tax rate of 25%. In addition, under the EIT Law, payments from BDL to us may be subject to a withholding tax. The EIT Law currently provides for a withholding tax rate of 20%. If Dehaier is deemed to be a non-resident enterprise, then it will be subject to a withholding tax at the rate of 10% on any dividends paid by its Chinese subsidiaries to Dehaier. In practice, the tax authorities typically impose the withholding tax rate of 10% rate, as prescribed in the implementation regulations; however, there can be no guarantee that this practice will continue as more guidance is provided by relevant government authorities. We are actively monitoring the proposed withholding tax and are evaluating appropriate organizational changes to minimize the corresponding tax impact.

 

The State Council issued the “Notice on Implementation of the Transition Period for Preferential Enterprise Income Tax,” or the “Transition Implementation Notice,” on December 26, 2007, which provides detailed rules on how preferential tax rates under previous income tax laws or regulations would transition to the uniform 25% EIT rate. In addition, entities that qualify as “high and new technology enterprises” will enjoy a 15% preferential tax rate under the EIT Law. The Ministry of Science and Technology, the Ministry of Finance and the State Administration of Taxation issued the “Measures on Qualification of High and New Technology Enterprises,” or “Circular 172,” on April 14, 2008, which provides detailed standards for “high and new technology enterprises.” In addition, according to the Notice on Prepayment of Enterprise Income Tax issued by the State Administration of Taxation, enterprises that have been certified as “high and new technology enterprises” shall pre-pay EIT at the rate of 25% temporarily until re-certified as “high and new technology enterprises” under Circular 172.

 

Under the current PRC laws, PRC government grants a preferential income tax rate of 15% to government-certified high technology companies, and under the new standard the period of validity for the certification of high technology companies is three years. In 2009, BDL updated its certification for “high technology” company. Therefore, BDL used a 15% income tax rate to calculate the income tax expense for the six months ended June 30, 2012 and 2011. The high technology certification will expire and be subject to renewal in September 2012. The tax rate for BTL is 25% in 2012 and 2011.

 

PRC Value Added Tax

 

All entities and individuals that are engaged in the businesses of sales of goods, provision of repair and placement services and importation of goods into China are generally subject to a VAT at a rate of 17% (with the exception of certain goods which are subject to a rate of 13%) of the gross sales proceeds received, less any VAT already paid or borne by the taxpayer on the goods or services purchased by it and utilized in the production of goods or provisions of services that have generated the gross sales proceeds.

 

PRC Business Tax

 

Companies in China are generally subject to business tax and related surcharges by various local tax authorities at rates ranging from 3% to 20% on revenue generated from providing services and revenue generated from the transfer of intangibles.

 

 

Critical Accounting Policies

 

Presentation in Accordance with US GAAP

 

We prepared our accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). These accounting principles require us to make judgments, estimates and assumptions on the reported amounts of assets and liabilities at the end of each fiscal period, and the reported amounts of revenues and expenses during each fiscal period. We continually evaluate these judgments and estimates based on our own historical experience, knowledge and assessment of current business and other conditions, our expectations regarding the future based on available information and assumptions that we believe to be reasonable.

 

Basis of Consolidation

 

The condensed consolidated financial statements include the accounts of Dehaier, BDL, its majority-owned subsidiary, and BTL. All significant inter-company transactions and balances are eliminated in consolidation.

 

A group of shareholders, including the Chief Executive officer, originally held more than 50% of the voting ownership interest of Dehaier, BDL and BTL. BTL is a variable interest entity (“VIE”), and BDL is the primary beneficiary. BTL owns a building, which is pledged as collateral for BDL’s bank loans. In exchange, BDL loans money to BTL to finance its operations. BTL’s primary operation is to provide repairs and transportation services to BDL’s customers. Because of these arrangements, BDL is the primary beneficiary of BTL, as the entity that is most closely associated with BTL. Management makes ongoing reassessments of whether BDL is the primary beneficiary of BTL.

 

The accounts of BTL are consolidated in the accompanying financial statements pursuant to Accounting Standards Codification (“ASC”) 810-10, “Consolidation.” As a VIE, BTL’s revenues are included in the Company’s service income, and its income from operations is consolidated with the Company’s. Because of the arrangements, the Company had a pecuniary interest in BTL that requires consolidation of the Company’s and BTL’s financial statements.

 

Use of Estimates

 

The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates are adjusted to reflect actual experience when necessary. Significant accounting estimates reflected in the Company’s condensed consolidated financial statements include revenue recognition, allowance for doubtful accounts, inventory obsolescence, warranty obligation, warrants liability, Stock-based compensation and useful lives of property and equipment. Actual results could differ from those estimates.

 

Accounts Receivable

 

Accounts receivable are recorded at net realizable value. Accounts receivable terms typically are 60-180 days from the end of the month in which services are provided or goods are delivered. Our typical trade receivable terms vary based on the type of customer. We general require 100% prepayment before delivering our products to individual clients. Our contract terms general require 10%-30% prepayment for our hospital and healthcare center clients, and the trade receivable term in contracts for those clients is generally between 60 and 90 days. Our contract terms general require 10% prepayment from our distributor clients, and the trade receivable term in contracts for those clients is generally between 60 and 180 days. With the exception of the prepayments we require in some cases, we generally do not require collateral or other security to support accounts receivable. An allowance, if required, is based on a combination of historical experience, aging analysis, and an evaluation of the collectability of specific accounts.

 

 

Prior to 2011, receivables were considered past due after 3 years and written off. Management determined this write-off policy by reviewing the decrease in likelihood of collection as a function of time and concluded that collectability of accounts receivable after three years was significantly impaired compared with collectability prior to such time. In 2011, after assessing the distributors’ economic factors and the Company’s historic experiences, management decided that receivables over 1 year are considered past due. Because this change was not retroactive, the current period’s net income and earnings per share are lower than the comparable period in 2011.

 

Fair Value of Financial Instruments

 

The carrying amounts reported in the consolidated financial statements for current assets and current liabilities approximate fair value due to the short-term nature of these financial instruments.

 

The Company follows the provisions of ASC 820-10, “Fair Value Measurements and Disclosures,” which establishes a single authoritative definition of fair value and a framework for measuring fair value and expands disclosure of fair value measurements for both financial and nonfinancial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flows) and the cost approach (cost to replace the service capacity of an asset or replacement cost). For purposes of ASC 820-10-15, nonfinancial assets and nonfinancial liabilities would include all assets and liabilities other than those meeting the definition of a financial asset or financial liability as defined in ASC 820-10-15-15-1A.

 

The Company adopted the provisions of ASC Topic 815 (formerly Emerging Issue Task Force 07-5), “Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity’s Own Stock.” ASC Topic 815 provides a framework for determining whether an instrument is indexed to an entity’s own stock. ASC Topic 815 became effective for the Company this period when warrants were issued in connection with the Company’s initial public offering (“IPO”). Such warrants are indexed to the Company’s common shares, which is traded in US dollars. Since the Company’s functional currency is the RMB, such warrants are considered liabilities. The fair value of the warrant liabilities is measured each reporting period with the resulting change in fair value recorded in the statement of operations. An increase of the warrants liability would decrease net income and earnings per share. A decrease in warrants liability would increase net income and earnings per share of the Company.

 

Revenue Recognition

 

The Company recognizes revenues when all the followings conditions have been satisfied:

 

•

Persuasive evidence an arrangement exists;

 

•

Delivery and/or installation has occurred (e.g., risks and rewards of ownership have passed);

 

•

The sales price is fixed or determinable; and

 

•

Collectability is reasonably assured.

 

All revenues are based on firm customer orders with fixed terms and conditions. Because the products are assembled to the customers’ specification, there is no right of return. The Company does not provide its customers with price protection or cash rebates. For products that include software, the software is an off-the-shelf package and an integral part of the products being delivered. The Company does not provide any significant post-sale customer support services and does not provide customers with upgrades. The software is incidental to the product as a whole. For products that do not require installation, revenues are recognized when the products are delivered. For products that require installation, revenues are recognized when the installation is completed.

 

 

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740-10, “Accounting for Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year; and, (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if, based on the weight of available positive and negative evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

 

ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken on a tax return. Under ASC 740-10, a tax benefit from an uncertain tax position taken or expected to be taken may be recognized only if it is “more likely than not” that the position is sustainable upon examination, based on its technical merits. The tax benefit of a qualifying position under ASC 740-10 would equal the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with a taxing authority having full knowledge of all the relevant information. A liability (including interest and penalties, if applicable) is established in the financial statements to the extent a current benefit has been recognized on a tax return for matters that are considered contingent upon the outcome of an uncertain tax position. Related interest and penalties, if any, are included as components of income tax expense and income taxes payable. The Company is awaiting resolution of certain complex tax issues and has not yet filed its previous years’ Value Added Tax (“VAT”) returns for some of its customers. However, all the potential VAT liabilities on these VAT returns were accrued and included in the accompanying condensed consolidated financial statements.

 

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

 

Not applicable.

 

Item 4.

Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

The Company maintains a system of controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

As of June 30, 2012, the Company carried out an evaluation, under the supervision of and with the participation of management, including its chief executive officer and chief financial officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. Based on the foregoing, the chief executive officer and interim chief financial officer concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) were effective in timely alerting them to information required to be included in the Company’s periodic SEC filings.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934, as amended) during the six or three months ended June 30, 2012 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 

PART II.              OTHER INFORMATION

 

Item 1.

Legal Proceedings

 

None.

 

Item 1A.

Risk Factors

 

Not applicable.

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

(a) None.

 

(b) None

 

(c) None.

 

Item 3.

Defaults upon Senior Securities

 

None.

 

Item 4.

Mine Safety Disclosures

 

Not applicable.

 

Item 5.

Other Information

 

None.

 

Item 6.

Exhibits

 

The following documents are filed herewith:

 

Exhibit Number		Document
3(i).1		Third Amended and Restated Articles of Association of the Registrant (1)
3(ii).1		Third Amended and Restated Memorandum of Association of the Registrant (1)
4.1		Specimen Share Certificate (1)
10.1		Form of Share Option Plan (1)
10.2		Translation of lease agreement for Product Center dated September 23, 2008 (1)
10.3		Translation of lease agreement for Principal Executive Office dated December 21, 2009, effective January 1, 2010 (1)
10.4		Distribution agreement with IMD (1)
10.5		Distribution agreement with Heyer (2)

 

 

10.6		Translation of form of independent distributor agreement (1)
10.7		Translation of Executive Officer Employment Agreement for Ping Chen (1)
10.8		Translation of Executive Officer Employment Agreement for Weibing Yang (1)
10.9		Translation of Executive Officer Employment Agreement for Aileen Qi(2)
10.10		Translation of Form of Purchase Agreement with Poverty Aid Office (1)
10.11		Translation of Production Agreement with Friend of Health (Chuzhou) Medical Technology Co., Ltd. (1)
10.12		Mortgage Contract between ICBC and BDL (1)
10.13		Indemnification and Guarantee Contract between Ping Chen and BTL (1)
10.14		Description of oral loan contract between BTL and BDL (1)
10.15		Loss Absorption Agreement between BDL, BTL and shareholders of BTL (1)
21.1		Subsidiaries of the Registrant (1)
31.1		Certifications pursuant to Rule 13a-14(a) or 15(d)-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (3)
31.2		Certifications pursuant to Rule 13a-14(a) or 15(d)-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (3)
32.1		Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (3)
32.2		Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (3)
99.1		Code of Business Conduct and Ethics (1)
99.2		Audit Committee Charter (4)
101.INS		XBRL Instance Document (5)
101.SCH		XBRL Taxonomy Extension Schema Document (5)
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document (5)
101.LAB		XBRL Taxonomy Extension Label Linkbase Document (5)
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document (5)
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document (5)

 

(1)	Incorporated by reference to the registrant’s registration statement on Form S-1, File no. 333-163041, filed on November 12, 2009, as amended.
(2)	Incorporated by reference to the registrant’s quarterly report on Form 10-Q, File no. 001-34661, filed on May 9, 2012.
(3)	Filed herewith.
(4)	Incorporated by reference to the registrant’s annual report on Form 10-K, File no. 001-34661, filed on September 30, 2010.
(5)	Furnished herewith.  In accordance with Rule 406T of Regulation S-T, the information in these exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	DEHAIER MEDICAL SYSTEMS LIMITED
August 13, 2012	By:	/s/    Ping Chen
		Ping Chen
		Chief Executive Officer
		(Principal Executive Officer) and
		Duly Authorized Officer

 

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

INDEX TO FINANCIAL STATEMENTS

 

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS		PAGE
Condensed Consolidated Balance Sheets as of June 30, 2012 and December 31, 2011		F-2
Condensed Consolidated Statements of Income and Comprehensive Income for the six and three months ended June 30, 2012 and 2011		F-3
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2012 and 2011		F-4
Notes to the Unaudited Condensed Consolidated Financial Statements		F-5

 

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 (UNAUDITED)

 

		June 30,				December 31,
		2012				2011
		US$				US$
ASSETS
CURRENT ASSETS:
Cash and cash equivalents			1,107,942				3,694,486
Accounts receivable -less allowance for doubtful accounts of $880,587 and $859,509			12,414,588				12,159,842
Other receivables			4,192,759				2,522,136
Prepayment and other current assets			7,288,515				6,714,001
Inventories, net			4,799,302				5,532,311
Tax receivable			503,853				888,452
Deferred tax asset			117,110				118,030
Total Current Assets			30,424,069				31,629,258
Property and equipment, net			3,063,366				3,348,533
Intangible assets, net			2,393,781				-
Total Assets			35,881,216				34,977,791
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Short-term borrowings			2,360,295				1,585,890
Accounts payable			39,040				32,925
Advances from customers			237,653				303,000
Accrued expenses and other current liabilities			319,836				349,158
Taxes payable			425,089				2,042,048
Warranty obligation			332,072				334,680
Total Current Liabilities			3,713,985				4,647,701
OTHER LIABILITIES
Warrants liability			286,041				96,469
Total Liabilities			4,000,026				4,744,170
Commitments and Contingency
Equity
Common shares, $0.002731 par value, 18,307,038 shares authorized, 4,570,000 and 4,560,000 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively			12,481				12,454
Additional paid in capital			13,359,602				13,281,374
Retained earnings			14,757,972				12,941,572
Accumulated other comprehensive income			2,359,421				2,585,488
Total Dehaier Medical Systems Limited shareholders' equity			30,489,476				28,820,888
Non-controlling interest			1,391,714				1,412,733
Total equity			31,881,190				30,233,621
Total liabilities and equity			35,881,216				34,977,791

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

  

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

		For the six months ended June 30,								For the three months ended June 30,
		2012				2011				2012				2011
		US$				US$				US$				US$
Revenue			10,299,059				10,665,490				6,983,128				7,712,784
Costs of revenue			(6,317,316	)			(6,826,494	)			(4,242,660	)			(4,871,247	)
Gross profit			3,981,743				3,838,996				2,740,468				2,841,537
Service income			132,915				156,428				92,518				71,595
Service expenses			(37,272	)			(61,372	)			(19,812	)			(20,675	)
General and administrative expense			(1,031,502	)			(1,016,167	)			(540,789	)			(512,641	)
Selling expense			(662,852	)			(694,493	)			(344,173	)			(454,792	)
Operating Income			2,383,032				2,223,392				1,928,212				1,925,024
Financial expenses (including interest expense of $64,904, $26,993, $37,741 and $10,816 for the six and three months ended June 30, 2012 and 2011, respectively)			(65,969	)			(27,472	)			(38,320	)			(11,859	)
Non-operating Income			395				-				395				-
Change in fair value of warrants liability			(92,067	)			149,867				107,441				140,341
Income before provision for income taxes and non-controlling interest			2,225,391				2,345,787				1,997,728				2,053,506
Provision for income tax			(416,468	)			(396,642	)			(319,420	)			(314,105	)
Net income			1,808,923				1,949,145				1,678,308				1,739,401
Non-Controlling interest in (income) loss			7,478				(5,654	)			12,072				(1,324	)
Net income attributable to Dehaier Medical Systems Limited			1,816,401				1,943,491				1,690,380				1,738,077
Net Income			1,808,923				1,949,145				1,678,308				1,739,401
Other comprehensive income
Foreign currency translation adjustments			(226,067	)			511,375				(268,862	)			324,095
Comprehensive Income			1,582,856				2,460,520				1,409,446				2,063,496
Comprehensive income attributable to the non-controlling interest			21,019				(28,591	)			13,253				(17,685	)
Comprehensive income attributable to Dehaier Medical Systems Limited			1,603,875				2,431,929				1,422,699				2,045,811
Earnings per share
-Basic			0.40				0.43				0.37				0.39
-Diluted			0.39				0.43				0.36				0.39
Weighted average number of common shares used in computation
-Basic			4,566,160				4,506,354				4,569,722				4,510,000
-Diluted			4,714,077				4,506,354				4,717,639				4,510,000

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

  

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

		For the six months ended June 30,
		2012				2011
		US$				US$
Cash flows from operating activities
Net income			1,808,923				1,949,145
Adjustments to reconcile net income to net cash used in operating activities
Stock-based compensation expense			124,077				59,300
Depreciation and amortization			246,448				219,976
Change in fair value of warrants liability			92,067				(149,867	)
Recovery of doubtful accounts			27,942				-
Changes in assets and liabilities:
Increase in accounts receivable			(282,688	)			(3,451,269	)
Increase in prepayments and other current assets			(522,831	)			(4,240,759	)
Decrease (Increase) in other receivables			(1,670,623	)			2,810
Decrease (Increase) in inventories			733,009				96,299
Decrease (Increase) in tax receivable			384,599				(911,942	)
Increase (Decrease) in accounts payable			6,115				1,153,882
Decrease in advances from customers			(65,347	)			(116,220	)
(Decrease) Increase in accrued expenses and other current liabilities			(31,931	)			9,502
(Decrease) Increase in tax payable			(1,616,959	)			2,022,812
Net cash used in operating activities			(767,199	)			(3,356,331	)
Cash flows from investing activities
Acquisition of machinery and software copyrights			(2,405,707	)			(62,302	)
Advances to related parties			-				(2,358	)
Net cash used in investing activities			(2,405,707	)			(64,660	)
Cash flows from financing activities
Proceeds from bank loan			2,373,145				1,542,680
Repayment of bank loan			(1,580,436	)			(1,533,604	)
Net cash provided by financing activities			792,709				9,076
Effect of exchange rate fluctuations on cash and cash equivalents			(206,347	)			496,552
Net decrease in cash and cash equivalents			(2,586,544	)			(2,915,363	)
Cash and cash equivalents at beginning of period			3,694,486				5,923,386
Cash and cash equivalents at end of period			1,107,942				3,008,023
Supplemental cash flow information
Income tax paid			779,678				13,260
Interest paid			64,904				26,993

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

1.	ORGANIZATION AND PRINCIPAL ACTIVITIES

 

Dehaier Medical Systems Limited (“Dehaier”) was incorporated in the British Virgin Islands in 2003 as a limited liability company. Dehaier distributes and provides after-sale services for medical equipment in China mainly through its majority-owned subsidiary Beijing Dehaier Medical Technology Co. Limited (“BDL”) and its affiliate Beijing Dehaier Technology Limited (“BTL”). On October 23, 2003, Dehaier established a wholly-owned subsidiary in Hong Kong, De-haier Medical System (Hong Kong) Limited (“DHK”), DHK was shut down on December 19, 2011 due to a change in business strategy. On November 9, 2011, Dehaier established a wholly-owned subsidiary in the United States, Breathcare LLC (“Breathcare”). Both BDL and BTL were incorporated in the People’s Republic of China (“PRC”). Dehaier, through its subsidiaries and affiliate, distributes branded, proprietary medical equipment, such as sleep apnea machines, ventilator air compressors, and oxygen generators. Standard product registration, product certification and quality management system have been established; ISO13485 industry standard has also already been passed. It also has the distribution rights for a number of international medical equipment suppliers for products including anesthesia equipment, patient monitors, mobile C-arm X-ray machines and other medical equipment accessories.

 

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).

 

In the opinion of the Company’s management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary to present fairly the condensed consolidated financial position, results of operations and cash flows of the Company for the periods presented. The results of operations for the six and three months ended June 30, 2012 are not necessarily indicative of operating results expected for the full year or future interim periods. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 19, 2012.

 

Basis of Consolidation

The condensed consolidated financial statements include the accounts of Dehaier, and its majority-owned and wholly-owned subsidiaries (collectively, the “Company”). All significant inter-company transactions and balances are eliminated in consolidation.

 

A group of shareholders, including the Chief Executive Officer, originally held more than 50% of the voting ownership interest of Dehaier, BDL and BTL. BTL is a variable interest entity (“VIE”), and BDL is the primary beneficiary. BTL owns a building which is pledged as collateral for BDL’s bank loans. In exchange, BDL loans money to BTL to finance its operations. BTL’s primary operation is to provide repairs and transportation services to BDL’s customers. Because of these arrangements, BDL is the primary beneficiary of BTL, as the entity that is most closely associated with BTL. Management makes ongoing reassessments of whether BDL is the primary beneficiary of BTL.

 

 

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

2.          SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Basis of Consolidation - Continued

 

The carrying amount and classification of BTL’s assets and liabilities included in the Condensed Consolidated Balance Sheets are as follows:

 

		June 30,				December 31,
		2012				2011
		US$				US$
Total current assets			445,921				425,464
Total assets			1,414,445				1,448,432
Total current liabilities			22,730				35,699
Total liabilities			22,730				35,699

 

The accounts of BTL are consolidated in the accompanying financial statements pursuant to Accounting Standards Codification (“ASC”) 810-10, “Consolidation”. As a VIE, BTL’s revenues are included in the Company’s service income, and its income from operations is consolidated with the Company’s. Because of the arrangements, the Company had a pecuniary interest in BTL that requires consolidation of the Company’s and BTL’s financial statements.

 

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates are adjusted to reflect actual experience when necessary. Significant accounting estimates reflected in the Company's condensed consolidated financial statements include revenue recognition, allowance for doubtful accounts, warranty obligation, warrants liability, Stock-based compensation and useful lives of intangible assets, and property and equipment. Actual results could differ from those estimates.

 

Accounts Receivable

Accounts receivable are recorded at net realizable value. Accounts receivable terms typically are net 60-180 days from the end of the month in which the services were provided, or when goods were delivered. The company generally does not require collateral or other security to support accounts receivable. An allowance, if required, is based on a combination of historical experience, aging analysis, and an evaluation of the collectibility of specific accounts. Prior to 2011, receivables were considered past due after 3 years. In 2011, after assessing the distributors’ economic factors and Company’s historic experience, management decided that receivables over 1 year will be considered past due. Management has determined that an allowance of $880,587 (RMB5,596,250) and $859,509 (RMB5,419,725) was appropriate at June 30, 2012 and December 31, 2011 respectively.

 

Advances to Suppliers and Advances from Customers

The Company, as is the common practice in the PRC, often makes advance payments to suppliers for unassembled parts, or receives advance payments from customers. Advances to suppliers were $4,754,727 and $4,348,847 as of June 30, 2012 and December 31, 2011, respectively, which were included in prepayments and other current assets. Advances from customers were $237,653 and $303,000 as of June 30, 2012 and December 31, 2011, respectively.

  

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Fair Value of Financial Instruments

The carrying amounts reported in the condensed consolidated financial statements for current assets and current liabilities approximate fair value due to the short-term nature of these financial instruments.

 

The Company adopted the provisions of ASC topic 815, “Derivatives and Hedging”. ASC topic 815 provides a framework for determining whether an instrument is indexed to an entity's own stock. ASC topic 815 became effective for the Company when warrants were issued in connection with the Company's initial public offering. Such warrants are indexed to the Company's stock, which is traded in US dollars. Since the Company's functional currency is the RMB, such warrants are considered liabilities. The fair value of the warrants liability is measured each reporting period with the resulting change in fair value recorded in the condensed consolidated statement of income and comprehensive income (see Note 12).

 

The accounting standards regarding fair value of financial instruments and related fair value measurements define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement, and enhance disclosure requirements for fair value measures.

 

The three levels are defined as follows:

 

·

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

·

Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

·

Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

Warrants liabilities qualify as financial instruments, and are carried on the condensed consolidated balance sheet at its fair value.

 

Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The fair value of the warrants was determined using the Black Scholes Model, with level 2 inputs, and the change is recorded in earnings.

 

Inventories

Inventories are stated at the lower of cost or market and consist of assembled and unassembled parts relating to medical devices. The Company reviews its inventory annually for possible obsolete goods and to determine if any reserves are necessary. The reserve for obsolescence was $50,756 (RMB322,556) and $51,154 (RMB322,556) as of June 30, 2012 and December 31, 2011, respectively, and the provision is included in the operating expenses in the condensed consolidated statements of operations.

  

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Property and Equipment

Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated on a straight-line basis over the following estimated useful lives:

 

Leasehold improvements	Shorter of the useful lives or the lease term
Building and land use rights	20-40 years
Machinery and equipment	10-15 years
Furniture and office equipment	5 years
Motor vehicles	5 years

 

Intangible Assets

Intangible assets are recorded at cost less accumulated amortization. Amortization are calculated on a straight-line basis over the following estimated useful lives:

 

Leasehold improvements	Shorter of the useful lives or the lease term
Software copyrights	20 years
Other software	5 years

 

Impairment of Long-Lived Assets

The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When these events occur, the Company measures impairment by comparing the carrying value of the long-lived assets to the estimated undiscounted future cash flows expected to result from the use of the asset and eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying amount over the fair value of the asset, is recognized. Management has determined no impairment exists at the balance sheet dates.

 

Revenue Recognition

The Company recognizes revenues when all the followings conditions have been satisfied:

*Persuasive evidence of an arrangement exists;

*Delivery and/or installation has occurred (e.g.,risks and rewards of ownership has passed);

*The sales price is fixed or determinable; and,

*Collectibility is reasonably assured.

 

All revenues are based on firm customer orders with fixed terms and conditions. Because the products are assembled to the customers’ specification, there is no right of return. The Company does not provide its customers with price protection or cash rebates. For products which include software, the software is an off-the-shelf package and an integral part of the products being delivered. The Company does not provide any significant post-sale customer support services and does not provide customers with upgrades. The software is incidental to the product as a whole. For products that do not require installation, revenues are recognized when the products are delivered. For products that require installation, revenues are recognized when the installation is completed.

 

For all service income, the Company recognizes the revenue upon the completion of the repairs when the equipment has been returned to and accepted by the customers.

 

In the PRC, value added tax (VAT) of 17% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities.

  

  

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Foreign Currency Translation

 

The accounts of Dehaier, BDL, BTL and DHK are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The accompanying condensed consolidated financial statements are presented in US dollars. Foreign currency transactions are translated into US dollars using fixed exchange rates in effect at the time of the transaction. Generally, foreign exchange gains and losses resulting from the settlement of such transactions are recognized in the condensed consolidated statements of income and comprehensive income. The foreign currency accounts of DHK, BDL and BTL are translated in accordance with ASC 830-10, “Foreign Currency Matters”. Assets and liabilities are translated at current exchange rates quoted by the People’s Bank of China at the balance sheet dates and revenues and expenses are translated at average exchange rates in effect during the periods. Resulting translation adjustments are recorded as other comprehensive income (loss) and accumulated as a separate component of equity.

 

Warranty Costs

 

The Company provides for the estimated cost of product warranties at the time revenue is recognized. The Company's warranty obligation is affected by product failure rates and material usage and service delivery costs incurred in correcting product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company's estimates, the Company may revise its estimated product warranty liability. The term of the product warranty is generally twelve months. The reserve for warranty costs was $332,072 (RMB2,110,361), $334,680 (RMB2,110,361) at June 30, 2012 and December 31, 2011, respectively. Warranty expense for the six and three months ended June 30, 2012 and 2011 was $25,081, $106,648, $16,770 and $77,121, respectively.

 

Earnings per Share

 

The Company follows the provisions of ASC 260-10, “Earnings per Share”. Basic earnings per share is computed by dividing net income attributable to holders of common shares by the weighted average number of common shares outstanding during the years. Diluted earnings per share reflect the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted into common shares. Common stock equivalents having anti-dilutive effect on earnings per share are excluded from the calculation of diluted earning s per share.

 

Value Added Tax

 

The Company reports revenues net of PRC’s value added tax for all the periods presented in the condensed consolidated statements of income and comprehensive income.

 

Stock-Based Compensation

The Company follows the provisions of ASC 718-10, “Compensation-Stock Compensation”. The Company has a share incentive plan which authorizes the issuance of up to 10% of the number of shares outstanding. Pursuant to the plan, the Company may issue options to purchase its common shares to employees and directors of the Company and its affiliates. The Company fair values share-based awards granted under the plan. Accordingly, compensation is measured on the grant date using appropriate valuation models.

 

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740-10, “Accounting for Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year; and, (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if, based on the weight of available positive and negative evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of June 30, 2012, the Company recorded a deferred tax asset for the temporary differences arising from allowance for doubtful accounts and certain accrued expenses. The company believes it can utilize the deferred tax asset to offset future taxable income. Therefore, no valuation allowance has been provided as of June 30, 2012 and December 31, 2011.

 

ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken on a tax return. Under ASC 740-10, a tax benefit from an uncertain tax position taken or expected to be taken may be recognized only if it is “more likely than not” that the position is sustainable upon examination, based on its technical merits. The tax benefit of a qualifying position under ASC 740-10 would equal the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with a taxing authority having full knowledge of all the relevant information. A liability (including interest and penalties, if applicable) is established in the financial statements to the extent a current benefit has been recognized on a tax return for matters that are considered contingent upon the outcome of an uncertain tax position. Related interest and penalties, if any, are included as components of income tax expense and income taxes payable. The Company had filed its 2008 and 2009 Value Added Tax (“VAT”) returns for some of its customers during the year 2011 and six months ended June 30, 2012. All the potential VAT liabilities on these VAT returns occurred in current period were also accrued and included in the accompanying condensed consolidated financial statements.

 

The implementation of ASC 740-10 resulted in no material liability for unrecognized tax benefits. As of June 30, 2012 and December 31, 2011, the Company did not have a liability for any unrecognized tax benefits. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits as income tax expense in the statement of operations. During the six months ended June 30, 2012 and 2011, the Company did not incur any interest or penalties.

 

Income tax returns for the year prior to 2009 are no longer subject to examination by tax authorities.

  

 

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

3.

OTHER RECEIVABLES

 

Other receivables consist of the following:

 

		June 30,				December 31,
		2012				2011
		US$				US$
Due from suppliers			553,705				350,679
Deposits for ongoing contracts			3,575,394				2,110,942
Employee advances			63,660				60,515
			4,192,759				2,522,136

 

4.

PREPAYMENT AND OTHER CURRENT ASSETS

 

Prepayment and other current assets consist of the following:

 

		June 30,				December 31,
		2012				2011
		US$				US$
Advances to suppliers			4,745,727				4,348,847
Prepayment for equipment purchase			2,435,068				2,300,415
Other prepaid expenses			107,720				64,739
			7,288,515				6,714,001

 

5.

PROPERTY AND EQUIPMENT, NET

 

Property and equipment consist of the following:

 

		June 30,				December 31,
		2012				2011
		US$				US$
Buildings			1,339,105				1,349,624
Land use rights			305,894				308,297
Plant and machinery			2,950,418				2,973,593
Automobiles			43,527				43,869
Office and computer equipment			476,328				503,833
			5,115,272				5,179,216
Less: Accumulated depreciation and amortization			(2,051,906	)			(1,830,683	)
Property and equipment, net			3,063,366				3,348,533

 

At June 30, 2012 and December 31, 2011, BTL’s building was pledged to a bank as collateral for short-term borrowings of RMB15,000,000 (US$2,360,295) and RMB10,000,000(US$1,585,890), respectively (see Note 8).

 

Depreciation and amortization expense was $246,448, $219,976, $127,724 and $110,603 for the six and three months ended June 30, 2012 and 2011, respectively.

 

 

 DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

5.

PROPERTY AND EQUIPMENT, NET (CONTINUED)

 

Land Use Rights

 

There is no private ownership of land in China. Land is owned by the government and the government grants land use rights for specified terms. The Company’s land use rights are reported at the purchase price (RMB1,944,000 in 2002).

 

6.

INTANGIBLE ASSETS, NET

 

		June 30,				December 31,
		2012				2011
		US$				US$
Software Copyright			2,361,373				-
Others			41,903				-
			2,403,276				-
Less: Accumulated and amortization			(9,495	)			-
Intangible assets, net			2,393,781				-

 

Approximate future minimum amortizations at June 30, for the next five years are 127,204 annually.

 

7.

TAX RECEIVABLE

 

Tax receivable consists of the following:

 

		June 30,				December 31,
		2012				2011
		US$				US$
Value added tax receivable			503,853				888,452

 

Enterprises or individuals who sell commodities, engage in repair and maintenance or import and export goods in the PRC are subject to a VAT in accordance with Chinese laws. The standard VAT is 17% of the gross sales price. A credit is available whereby VAT paid on the purchases of unassembled medical components of the Company’s product used in contract and production can be used to offset the VAT due on sales of the product.

 

The tax receivable as of June 30, 2012 and December 31, 2011 represents VAT credit on the purchased products. These amounts can be used to offset the VAT due on sales of the finished product.

 

8.

SHORT-TERM BORROWINGS

 

The Company has a line of credit for RMB10,000,000 with a commercial bank in China to finance its working capital. The credit line bears interest at a variable rate and is renewed annually on May 14th. Average interest rates for the six months ended June 30, 2012 and 2011 were 7.22% and 5.84%, respectively. Pursuant to the terms of the agreement, the line of credit is secured by BTL’s building (see note 5) and guaranteed by BDL and an officer of the Company.

 

On May 14, 2012, the bank renewed the Company's credit line that bears interest at a variable rate with payments due on March 14, 2013 and May 14, 2013 for RMB3,000,000 and RMB7,000,000, respectively.

 

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

8.

SHORT-TERM BORROWINGS (CONTINUED)

 

On February 2, 2012, the Company entered into a new loan agreement with Nanjing Bank Company Limited (Beijing Branch) in the amount of $791,315 (RMB 5,000,000) with floating interest rate which was approximately 8.2% per year, due on January 30, 2013. Pursuant to the terms of the agreement, the line of credit is guaranteed by an officer of the Company.

 

9.

NON-CONTROLLING INTEREST

 

Non-controlling interest consists of the following:

 

		June 30,				December 31,
		2012				2011
		US$				US$
Original paid-in capital			384,211				384,211
Retained Earnings			737,215				744,693
Accumulated other comprehensive income			270,288				283,829
			1,391,714				1,412,733

 

10.

COMMITMENTS AND CONTINGENCY

 

Leases

 

The lease commitments are for office premises and a warehouse facility, all of which are classified as operating leases. These non-cancelable leases have lease terms expiring through December 2012 for one year. Approximate future minimum lease payments under these leases at June 30, 2012, are $50,000 for the twelve months ending June 30, 2013.

 

Rent expense for the six and three months ended June 30, 2012 and 2011 was $43,467, $72,155, $21,989 and $54,876, respectively.

 

Employment Contracts

 

Under the PRC labor law, all employees have signed employment contracts with the Company. Management employees have employment contracts with terms up to three years and non-management employees have a one year employment contract renewable on an annual basis.

 

Contingency

 

The Labor Contract Law of the People’s Republic of China, requires employers to assure the liability of the severance payments if employees are terminated and have been working for the employers for at least two years prior to January 1, 2008. The Company has estimated its possible severance payments of approximately $270,000 and $235,000 as of June 30, 2012 and December 31, 2011, respectively, which have not been reflected in its condensed consolidated financial statements, because it is more likely than not that this will not be paid or incurred.

 

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

11.

EQUITY

 

Common Shares

 

On March 8, 2011, Dehaier issued 10,000 unregistered common shares to an investment relations firm. The fair value of the shares on the issuance date based on the closing price was $59,300.

 

On November 16, 2011, Dehaier issued 50,000 unregistered common shares to a consulting firm. The fair value of the shares on the issuance date based on the closing price was $84,250.

 

On January 9, 2012, Dehaier issued 5,000 restrict unregistered common shares to an independent contractor. The fair value of the shares on the issuance date based on the closing price was $11,000.

 

On April 5, 2012, Dehaier issued 5,000 restrict unregistered common shares to an independent contractor. The fair value of the shares on the issuance date based on the closing price was $12,000.

 

Statutory Surplus Reserves

 

A PRC company is required to make appropriations to statutory surplus reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (“PRC GAAP”). Appropriations to the statutory surplus reserve is required to be at least 10% of the after tax net income determined in accordance with PRC GAAP until the reserve is equal to 50% of the entity’s’ registered capital. 

 

The statutory surplus reserve fund is non-distributable other than during liquidation and can be used to fund previous years’ losses, if any, and may be utilized for business expansion or converted into share capital by issuing new shares to existing shareholders in proportion to their shareholding or by increasing the par value of shares currently held by them, provided that the remaining statutory surplus reserve balance after such issue is not less than 25% of the registered capital.

 

Since Dehaier is a British Virgin Islands’ company, it will not be subject to the statutory surplus reserve provisions. BDL is a joint-venture company and the statutory surplus reserve provisions will be determined by its board of directors. As of June 30, 2012, BDL’s board of directors has not yet made such determination. Therefore, no amount was allocated to the statutory surplus reserve account.

 

BTL appropriated 10% of its net profits as statutory surplus reserve, which is included as part of the non-controlling interest in the equity section. For the six months ended June 30, statutory surplus reserve activity was as follows:  

 

		For the six months ended June 30, 2012
		US$
Balance at December 31, 2011			74,469
Addition to statutory reserves			(748	)
Balance at June 30, 2012			73,721

 

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

11.

EQUITY (CONTINUED)

 

Stock Option Plan

 

Under the employee stock option plan, the Company’s stock options expire five years from the date of grant. On December 29, 2011, the Company entered into five-year agreements with its employees and directors. In connection with their services, the Company issued an aggregate of 450,000 options to acquire the Company’s common shares at an exercise price of $1.45 per share. The options vest in equal annually installments over the five years of the agreements. As of December 29, 2011, none of the 450,000 options have been fully vested.

 

The Company valued the stock options using the Black-Scholes model with the following assumptions:

 

		Expected Terms (years)				Expected Volatility				Dividend Yield				Risk Free Interest Rate				Grant Date Fair Value
Employees			5				126	%			0	%			0.83	%			1.45
Directors and officers			5				126	%			0	%			0.83	%			1.45

 

The following is a summary of the option activity:

 

Stock options		Shares				Weighted Average Exercise Price				Aggregate Intrinsic Value
Outstanding as of December 31, 2011			450,000			$	1.45
Granted			-
Forfeited			-
Exercised			-
Outstanding as of June 30, 2012			450,000			$	1.45			$	400,500

 

Following is a summary of the status of options outstanding and exercisable at June 30, 2012:

 

Outstanding options												Exercisable options
Average Exercise price				Number				Average remaining contractual life (years)				Average Exercise price				Number				Average remaining contractual life (years)
$	1.45				450,000				9.5			S	1.45				90,000				9.5

 

For the six and three months ended June 30, 2012 and 2011, the Company recognized $54,780, $0, $27,390 and $0, respectively, as compensation expense under its stock option plan.

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

12.

WARRANTS

 

On April 21, 2010, the Company issued to Anderson & Strudwick Incorporated (“A&S”) 150,000 warrants, as a portion of the placement commission for the IPO. On the same day, the Company granted a total of 7,500 warrants to Hawk Associates Inc.(“Hawks”), the Company’s investor relations consultancy. On January 10, 2012, the Company issued 100,000 warrants to FirsTrust Group, Inc., (“FirsTrust”), the Company’s investor relations consultancy. The Company had 257,500 warrants outstanding as of June 30, 2012. All the warrants issued to “A&S” have the right to purchase one share of common stock for an exercise price of $10.00 per share with a term of 5 years. All the warrants granted to Hawks have the right to purchase one share of common stock for an exercise price of $9.60 per share with a term of 5 years. All the warrants granted to Firs Trust have the right to purchase one share of common stock for an exercise price of $4.00 per share with a term of 5 years.

 

The fair value of the outstanding warrants at June 30, 2012 were calculated using the Black Scholes Model with the following assumptions:

 

Market price per share (USD/share)			1.66
Exercise price (USD/share)			4.00 to 10.00
Risk free rate			0.72%, 0.51%
Dividend yield			-
Expected term/Contractual life (years)			2.81 to 4.53
Expected volatility			153.9%

 

The following table sets forth by level within the fair value hierarchy of our financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2012 and December 31, 2011, respectively.

  

		Carrying Value at  June 30, 2012				Fair Value Measurement at June 30, 2012
						Level 1				Level 2				Level 3
Warrants liability		$	286,041			$	-			$	286,041			$	-

 

The following is a reconciliation of the beginning and ending balances of warrants liability measured at fair value on a recurring basis using Level 2 inputs:

 

		June 30, 2012				December 31, 2011
		US$				US$
Beginning balance			96,469				318,109
Warrants issued			97,505				-
Fair value change of the issued warrants included in earnings			92,067				(221,640	)
Ending balance			286,041				96,469

 

Following is a summary of the warrants activity:

 

		Number				Weighted Average Exercise Price				Weighted Average Remaining Contractual Life
Outstanding as of December 31, 2011			157,500			$	9.98				3.31
Granted			100,000
Forfeited			-
Exercised			-
Outstanding as of June 30, 2012			257,500			$	7.66				3.48

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

13.

INCOME TAXES

 

British Virgin Islands

 

Dehaier is a tax-exempt company incorporated in the British Virgin Islands. BDL and BTL were incorporated in the PRC and are governed by the PRC laws.

 

Hong Kong

 

DHK is subject to Hong Kong profits tax at a rate of 17.5% on its assessable profits. No Hong Kong profits tax has been provided as the Company did not have any taxable profit that was earned in or derived from Hong Kong during the years presented.

 

PRC

 

PRC enterprise income tax is calculated based on the Enterprise Income Tax Law (the “EIT Law”). Under the EIT Law, a unified enterprise income tax rate of 25% and unified tax deduction standards will be applied equally to both domestic-invested enterprises and foreign-invested enterprises.

 

Under the current PRC laws, PRC government grants a preferential income tax rate of 15% to government-certified high technology companies, and under the new standard the period of validity for the certification of high technology companies is three years. In 2009, BDL updated its certification for “high technology” company. Therefore, BDL used a 15% income tax rate to calculate the income tax expense for the six months ended June 30, 2012 and 2011. The high technology certification will expire and be renewed in September 2012.

 

The tax rate for BTL is 25% in 2012 and 2011.

 

United States

Breathcare is a limited liability company and is not subject to federal income tax. As of June 30, 2012, Breathcare was inactive.

 

 

DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

14.

CONCENTRATIONS

 

Major Customers

 

For the six and three months ended June 30, 2012, approximately 10% and 15% of the Company’s revenues was received from one customer. For the six and three months ended June 30, 2011, approximately 13% and 15% of the Company’s revenues was received from one customer.

 

At June 30, 2012 and 2011, receivables from four customers were approximately 9%, 9%, 8%, 8% and 12%, 10%, 10%, 9%, respectively.

 

Revenues

 

For the six and three months ended June 30, 2012 and 2011, the Company’s three top selling products accounted, in the aggregate, for approximately 76%, 80%, 75%, and 82%, respectively, of its total net revenues.

 

The following represents the revenues by product line, all derived from China:

 

		For the six months ended June 30,								For the three months ended  June 30,
		2012				2011				2012				2011
		US$				US$				US$				US$
Product Line
Medical Devices			8,687,340				8,658,862				5,763,039				5,915,161
Respiratory and Oxygen Homecare			1,611,719				2,006,628				1,220,089				1,797,623
			10,299,059				10,665,490				6,983,128				7,712,784

 

15.

SUBSEQUENT EVENTS

 

In July 2012, the Company received approved SFDA registration certificate for proprietary homecare medical CPAP product of Model DHR-CPAP-C5. The certificate is valid until July 1, 2016 and allows the Company to sell the products in mainland China.